single technology appraisal (STA)
Liraglutide for the treatment of type 2 diabetes : a single technology appraisal
... This paper presents a summary of the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s ...
10
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal
... its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical ...
18
Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy : An Evidence Review Group Perspective of a NICE Single Technology Appraisal
... the single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited Janssen to submit evidence on the clinical and cost-effectiveness of their drug ...
23
Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
... The National Institute for Health and Care Excellence (NICE) invited Dendreon, the company manufacturing sipuleucel-T, to submit evidence for the clinical and cost-effectiveness of sipuleucel-T for asymptomatic or ...
13
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
... NICE single technology appraisal (STA) process usually covers new technologies within a single indication, soon after they have received UK marketing authorisation ...the technology, ...
22
Pembrolizumab for previously treated advanced or metastatic urothelial cancer : an evidence review group perspective of a NICE single technology appraisal
... The single technology appraisal (STA) process was specifically designed to appraise a single product for a single ...health technology submits a report, which is critically ...
20
Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
... NICE Single Technology Appraisal (STA) process usually covers new single health technologies within a single indication, soon after the UK market authorisation ...NICE Appraisal ...
26
Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
... NICE Single Technology Appraisal (STA) process usually covers new single health technologies within a single indication, soon after the UK market authorisation ...the technology, ...
25
Venetoclax for treating chronic lymphocytic leukaemia : an evidence review group perspective of a NICE single technology appraisal
... the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within its ...
9
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
... its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical ...
19
Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
... NICE Single Technology Appraisal (STA) process usually covers new single health technologies within a single indication, soon after the UK market authorisation ...NICE Appraisal ...
28
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
... its single technology appraisal pro- 10 cess, the National Institute for Health and Care Excellence 11 (NICE) invited the company (Lundbeck) marketing 12 nalmefene (Selincro) to submit evidence of ...
17
The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process
... (NICE) single technology appraisal process, independent evi- dence review groups (ERGs) critically appraise a company’s submission relating to a specific technology and ...completed ...
9
Ixazomib for relapsed or refractory multiple myeloma : review from an evidence review group on a NICE single technology appraisal
... manufacturer of a particular technology submits evidence in support of the clinical and cost effective use of its product in one single indication. NICE commissioned an Evidence Review Group (ERG), in this ...
21
Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective
... Methods: The ERG produced a critical review of the evidence for the clinical and cost effectiveness of the technology based upon the manufacturers’ submission (MS) to NICE. Results: Clinical effectiveness evidence ...
20
A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
... submissions to determine whether or not the suggestions set out here have been heeded by manufacturers. Manu- facturers should be offered training and support to ensure that submissions meet the needs of the AC. Further ...
6
NICE guidance : a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium
... final appraisal deter- ...NICE appraisal for many years) is that the length of the Appraisal Consultation Decisions and Final Appraisal Determination has increased over the ...the ...
13
Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
... The ERG’s critical appraisal identified a number of issues relating to the company’s model and analysis. The most pertinent of these relate to: (i) the weaknesses of the NMA; (ii) inclusion of two lines of bDMARDs ...
20
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
... Several important methodological issues were highlighted during the appraisal. The manufacturer made implausible assumptions regarding the resource use associated with different health states included in the ...
13
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
... through the sequences of treatments being compared. For each treatment excluding best supportive care (BSC), patients may achieve good, moderate or no EULAR response, which is assessed at 6 months. The EULAR response ...
18